BACKGROUND: ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) consists of two identical prospective open-label, multicenter, phase 3 studies (MBG311 and MBG312) evaluating the prognostic usefulness of (123)I-mIBG scintigraphy for identifying subjects with heart failure who will experience a major adverse cardiac event. METHODS: Subjects with NYHA class II and III heart failure and left ventricular ejection fraction < or = 35% were eligible for the trials. Subjects underwent planar and SPECT (123)I-mIBG myocardial imaging, as well as echocardiography and gated SPECT (99m)Tc-tetrofosmin myocardial perfusion imaging. Subjects are then monitored on a regular basis for 2 years. Time to first occurrence of one of the following--NYHA class progression; potentially life-threatening arrhythmic event (including ICD discharge); or cardiac death, as verified by an independent adjudication panel---will be analyzed in comparison to quantitative parameters derived from (123)I-mIBG imaging. The primary efficacy analysis will employ the heart/mediastinum ratio on 4-hour delayed planar imaging, while secondary efficacy analyses will examine quantitative results from both planar and SPECT (123)I-mIBG images, as well as from (99m)Tc-tetrofosmin SPECT and echocardiography. CONCLUSION: The results of the ADMIRE-HF trials will provide prospective validation of the potential role of (123)I-mIBG scintigraphy in assessing prognosis and developing management strategies for patients with heart failure.
BACKGROUND: ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) consists of two identical prospective open-label, multicenter, phase 3 studies (MBG311 and MBG312) evaluating the prognostic usefulness of (123)I-mIBG scintigraphy for identifying subjects with heart failure who will experience a major adverse cardiac event. METHODS: Subjects with NYHA class II and III heart failure and left ventricular ejection fraction < or = 35% were eligible for the trials. Subjects underwent planar and SPECT (123)I-mIBG myocardial imaging, as well as echocardiography and gated SPECT (99m)Tc-tetrofosmin myocardial perfusion imaging. Subjects are then monitored on a regular basis for 2 years. Time to first occurrence of one of the following--NYHA class progression; potentially life-threatening arrhythmic event (including ICD discharge); or cardiac death, as verified by an independent adjudication panel---will be analyzed in comparison to quantitative parameters derived from (123)I-mIBG imaging. The primary efficacy analysis will employ the heart/mediastinum ratio on 4-hour delayed planar imaging, while secondary efficacy analyses will examine quantitative results from both planar and SPECT (123)I-mIBG images, as well as from (99m)Tc-tetrofosmin SPECT and echocardiography. CONCLUSION: The results of the ADMIRE-HF trials will provide prospective validation of the potential role of (123)I-mIBG scintigraphy in assessing prognosis and developing management strategies for patients with heart failure.
Authors: G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler Journal: Circulation Date: 1996-05-01 Impact factor: 29.690
Authors: P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota Journal: J Nucl Med Date: 1999-06 Impact factor: 10.057
Authors: A Cohen-Solal; Y Esanu; D Logeart; F Pessione; C Dubois; G Dreyfus; R Gourgon; P Merlet Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: M Ungerer; F Hartmann; M Karoglan; A Chlistalla; S Ziegler; G Richardt; M Overbeck; H Meisner; A Schömig; M Schwaiger Journal: Circulation Date: 1998-01-20 Impact factor: 29.690
Authors: M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson Journal: N Engl J Med Date: 1982-07-22 Impact factor: 91.245
Authors: Ji Chen; Russell D Folks; Liudmila Verdes; Daya N Manatunga; Arnold F Jacobson; Ernest V Garcia Journal: J Nucl Cardiol Date: 2011-12-07 Impact factor: 5.952
Authors: Yanli Zhou; Weihua Zhou; Russell D Folks; Daya N Manatunga; Arnold F Jacobson; Jeroen J Bax; Ernest V Garcia; Ji Chen Journal: J Nucl Cardiol Date: 2014-05-24 Impact factor: 5.952
Authors: Fadi G Hage; Himanshu Aggarwal; Kanan Patel; Ji Chen; Arnold F Jacobson; Jaekyeong Heo; Ali Ahmed; Ami E Iskandrian Journal: J Nucl Cardiol Date: 2013-10-30 Impact factor: 5.952